Trial reportBMJ open2014
Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study.
Trial report in BMJ open, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders.Clinical pharmacology and therapeutics · 2026Pooled it
- Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease.The Cochrane database of systematic reviews · 2020Pooled it
- Memantine for dementia.The Cochrane database of systematic reviews · 2019Pooled it
- Effectiveness of acetylcholinesterase inhibitors and memantine in patients affected by severe dementia.GeroScience · 2026Article
- Memantine: updates from the past decade and implications for future novel therapeutic applications.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study.Alzheimer's research & therapy · 2024Observational
- [Dementia with Lewy bodies: old and new knowledge-Part 2: treatment].Der Nervenarzt · 2024Review
- Review
- A Randomized Placebo-Controlled Study of a Transcranial Photobiomodulation Helmet in Parkinson's Disease: Post-Hoc Analysis of Motor Outcomes.Journal of clinical medicine · 2023Article
- New evidence on the management of Lewy body dementia.The Lancet. Neurology · 2020Review
- Burden of Disease and Current Management of Dementia with Lewy Bodies: A Literature Review.Neurology and therapy · 2019Review
- Polypharmacy in Parkinson's disease: risks and benefits with little evidence.Journal of neural transmission (Vienna, Austria : 1996) · 2019Article
- Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis.Experimental and therapeutic medicine · 2019Article
- A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and Treatment.Neurology and therapy · 2018Review
- NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.Translational psychiatry · 2018Review
- Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Article
- Diagnosis and Management of Cognitive and Behavioral Changes in Dementia With Lewy Bodies.Current treatment options in neurology · 2017Review
- New Therapeutic Strategies for Lewy Body Dementias.Current neurology and neuroscience reports · 2017Review
- Lewy Body Disorders.Neurologic clinics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect on survival of treatment with memantine in patients with dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD).
methods75 patients with DLB and PDD were included in a prospective double-blinded randomised placebo-controlled trial (RCT) of memantine, of whom long-term follow-up was available for 42. Treatment response was recorded 24 weeks from baseline and measured by Clinical Global Impression of Change (CGIC). The participants were grouped as responders (CGIC 1-3) or non-responders (CGIC 4-7). The 24-week RCT was followed by open-label treatment and survival was recorded at 36 months.
resultsAfter 36-month follow-up, patients in the memantine group had a longer length of survival compared with patients in the placebo group (log rank x²=4.02, p=0.045). Within the active treatment group, survival analysis 36 months from baseline showed that the memantine responders, based on CGIC, had higher rates of survival compared with the non-responders (log rank x²=6.595, p=0.010). Similar results were not seen in the placebo group.
conclusionsEarly treatment with memantine and a positive clinical response to memantine predicted longer survival in patients with DLB and PDD. This suggests a possible disease-modifying effect and also has implications for health economic analysis. However, owing to the small study sample, our results should merely be considered as generating a hypothesis which needs to be evaluated in larger studies. TRIAL REGISTRATION NUMBER: ISRCTN89624516.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.